Department of Medical Oncology, Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.
Department of Medical Oncology, Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London W6 8RF, UK.
Hematol Oncol Clin North Am. 2024 Dec;38(6):1265-1276. doi: 10.1016/j.hoc.2024.08.019. Epub 2024 Sep 24.
Gestational trophoblastic disease encompasses a spectrum of premalignant and malignant conditions. While centralized care models significantly improve survival rates, many countries still lack such specialized centers, leading to preventable deaths. Current research focuses on refining diagnostic and treatment methods, aiming to better predict the risk of malignancy and reduce the need for aggressive therapies. Immunotherapy has emerged as a promising treatment modality, offering high cure rates with fewer side effects compared to traditional chemotherapy. Global efforts must continue to expand access to specialized care and integrate new therapies to improve outcomes and reduce treatment-related harm.
妊娠滋养细胞疾病涵盖了一系列的癌前病变和恶性疾病。虽然集中式的治疗模式显著提高了生存率，但许多国家仍然缺乏这样的专门中心，导致可预防的死亡。目前的研究重点是改进诊断和治疗方法，旨在更好地预测恶性肿瘤的风险，并减少对激进治疗的需求。与传统化疗相比，免疫疗法已成为一种有前途的治疗方式，具有更高的治愈率和更少的副作用。全球必须继续努力扩大获得专门治疗的机会，并整合新的治疗方法，以改善结果并减少与治疗相关的伤害。
